Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.
The identification and characterization of tumor-associated antigens (TAAs) and their use in antigen mini-arrays for cancer immunodiagnosis has been of interest recently as an approach to cancer detection. In this study, autoantibodies in sera from a patient with HCC were used as probes to immunoscreen a HepG2 cDNA expression library for the identification of TAAs involved in malignant liver transformation. Recombinant proteins from two genes identified in this manner, Sui1 and RalA were expressed, purified and used as antigens in immunoassays to detect the presence of antibodies in sera from 77 patients with HCC, 30 with chronic hepatitis (CH), 30 with liver cirrhosis (LC) and 82 normal human sera (NHS). The prevalence of antibody to Sui1 and RalA in HCC were 11.7% (9/77) and 19.5% (15/77), respectively, which were significantly higher than prevalence in liver cirrhosis (3.3% and 3.3%), chronic hepatitis (0% and 0%) and normal human sera (0% and 0%). When Sui1 and RalA were added to a panel of eight other TAAs used in a previous study, the final cumulative prevalence of anti-TAA antibodies in HCC to the 10 TAA array was raised to 66.2% (51/77). The specificity for HCC compared with LC, CH and NHS, was 66.7%, 80.0%, and 87.8%, respectively. When anti-TAA was added to abnormal serum AFP as combined diagnostic markers, it raised the diagnostic sensitivity from 66.2% to 88.7%. AFP and anti-TAA were independent markers and the simultaneous use of these two markers significantly resulted in the increased sensitivity of HCC detection.
Chen
Yao
Y
Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
Zhou
Yusen
Y
Qiu
Suimin
S
Wang
Kaijuan
K
Liu
Siwei
S
Peng
Xuan-Xian
XX
Li
Junfeng
J
Tan
Eng M
EM
Zhang
Jian-Ying
JY
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood* / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology*; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000276:immunology; D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000096:biosynthesis; D004797:Enzyme-Linked Immunosorbent Assay; D039642:Eukaryotic Initiation Factors / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007159:Immunologic Tests; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012015:Reference Standards; D012680:Sensitivity and Specificity; D015854:Up-Regulation; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000032:analysis; D020725:ral GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D018076:DNA, Complementary; C410108:EIF1 protein, human; D039642:Eukaryotic Initiation Factors; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; C492198:RALA protein, human; D020725:ral GTP-Binding Proteins
N Engl J Med. 2005 Sep 22;353(12):1224-35
16177248
Hepatology. 2002 Nov;36(5 Suppl 1):S84-92
12407580
J Clin Pathol. 1996 Apr;49(4):295-9
8655704
Mol Cell Biol. 1992 Jan;12(1):248-60
1729602
Mol Cell Biol. 2001 Sep;21(17):5958-69
11486034
Cancer Immun. 2001 Mar 30;1:3
12747764
Oncogene. 1999 Mar 4;18(9):1677-87
10208429
Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12
15508073
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9
11752453
J Biol Chem. 2003 Sep 26;278(39):37231-40
12857727
Cancer Res. 2002 Feb 15;62(4):982-5
11861368
J Hepatol. 1997 Jun;26(6):1255-65
9210612
Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43
12582023
Clin Cancer Res. 2003 Nov 1;9(14):5120-6
14613989
Biochem Biophys Res Commun. 1995 Feb 27;207(3):1029-37
7864889
J Hepatol. 2007 Jan;46(1):107-14
17067715
J Invest Dermatol. 2004 Feb;122(2):414-22
15009724
Gut. 1978 Apr;19(4):294-9
77242
Cancer. 1993 Jan 1;71(1):26-35
8380118
Oncogene. 2005 Jan 13;24(3):329-35
15467745
Hepatology. 1996 May;23(5):1181-8
8621152
Oncogene. 2002 Jul 25;21(32):5006-15
12118381
J Exp Med. 1998 Apr 20;187(8):1163-7
9547328
Br J Cancer. 1997;75(2):236-40
9010032
J Biomed Sci. 2000 Mar-Apr;7(2):152-9
10754390
J Exp Med. 1999 Apr 5;189(7):1101-10
10190901
Hepatology. 1989 May;9(5):751-5
2540084
Clin Immunol Immunopathol. 1988 May;47(2):121-41
3280190
Cancer Cell. 2005 Jun;7(6):533-45
15950903
Cell. 1991 Nov 29;67(5):841-2
1959131
N Engl J Med. 1986 Mar 20;314(12):736-9
3485248
Lancet. 2009 Feb 21;373(9664):673-83
19231634
Hepatology. 2004 Jul;40(1):252-9
15239109
Br J Cancer. 1976 Sep;34(3):286-90
974002
J Hepatol. 2007 Jan;46(1):9-11
17112623
Life Sci. 2005 Nov 4;77(25):3231-41
15985268
J Clin Immunol. 2002 Mar;22(2):98-105
11998899
Curr Biol. 1998 Apr 9;8(8):471-4
9550702
Curr Opin Cell Biol. 2000 Apr;12(2):157-65
10712923
Clin Exp Immunol. 2001 Jul;125(1):3-9
11472419
Immunol Rev. 2008 Apr;222:328-40
18364012
RNA. 1999 Jun;5(6):794-804
10376878
J Am Soc Nephrol. 2005 Mar;16(3):646-57
15677310
EMBO Rep. 2003 Aug;4(8):800-6
12856001
J Clin Invest. 1993 Nov;92(5):2419-26
8227358